Recruiting Coordinator (Contract)
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
The Opportunity
At Nurix Therapeutics, you'll help build the teams advancing groundbreaking therapies for patients. As a Recruiting Coordinator (Contract), you'll be at the center of the hiring process—creating exceptional candidate experiences, partnering with recruiters and hiring managers, and ensuring every interview and interaction runs seamlessly.
If you're highly organized, thrive in a fast-paced environment, and enjoy connecting people with meaningful opportunities, we'd love to meet you.
This contract role is based onsite in our Brisbane, CA headquarters.
What You'll Do
What You'll Bring
Why Join Nurix?
At Nurix, you'll support the growth of teams working at the forefront of targeted protein degradation and AI-powered drug discovery. Your work will directly contribute to bringing innovative therapies closer to patients while helping create an exceptional hiring experience for talent joining our mission.

Important Notice to Candidates: Nurix representatives with never conduct interviews by text and will never request personal financial information or ask candidates to purchase equipment.
At Nurix Therapeutics, we aim to fundamentally change the way disease is treated using degrader-based medicines. Our journey began with a vision to harness the power of the cell’s natural protein degradation machinery, the ubiquitin-proteasome system, to create a new class of therapeutics that can overcome the limitations of current treatments.